梯瓦制药的妥瑞氏综合征疗法获美国FDA优先审评

格隆汇
Aug 19
梯瓦制药宣布,美国食品药品监督管理局(FDA)已对其提交的妥瑞氏综合征实验性儿童疗法ecopipam上市申请授予优先审评资格。FDA已针对ecopipam新药申请设定目标行动日期,预计为2027年第一季度末。妥瑞氏综合征的特征是儿童时期最初出现的不自主运动和发声抽动,在美国约影响10万名儿童和青少年。公司表示,如果获批,ecopipam将成为十多年来首个获批的妥瑞氏综合征疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10